WIP1 deficiency inhibits HTLV-1 Tax oncogenesis: novel therapeutic prospects for treatment of ATL? by unknown
Gillet et al. Retrovirology 2012, 9:115
http://www.retrovirology.com/content/9/1/115VIEWPOINTS Open AccessWIP1 deficiency inhibits HTLV-1 Tax oncogenesis:
novel therapeutic prospects for treatment of ATL?
Nicolas Gillet1,2, Alexandre Carpentier1,2, Pierre-Yves Barez1,2 and Luc Willems1,2*Abstract
Attenuation of p53 activity appears to be a major step in Human T-lymphotropic virus type 1 (HTLV-1) Tax
transformation. However, p53 genomic mutations are late and rather infrequent events in HTLV-1 induced Adult T
cell leukemia (ATL). The paper by Zane et al. shows that a mediator of p53 activity, Wild-type p53-induced
phosphatase 1 (Wip1), contributes to Tax-induced oncogenesis in a mouse model. Wip1 may therefore be a novel
target for therapeutic approaches.
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Human T-lymphotropic virus type 1 (HTLV-1) is a δ−re-
trovirus that infects about 25 million people worldwide
[1,2]. HTLV-1 causes Adult T-cell leukemia-lymphoma
(ATLL) and a neurodegenerative disease called HTLV-
induced myelopathy - tropical spastic paraparesis (HAM/
TSP). Only a minority of infected subjects (~4%) will de-
velop either ATL or HAM/TSP usually after several
decades of latency. Although the mechanisms are still in-
completely understood, experimental evidence shows that
two factors, Tax and HBZ, are major players in viral repli-
cation and oncogenesis [3-5]. The HBZ gene is transcribed
from the proviral complementary strand initiating from
the 30-LTR promoter. HBZ activates JunD transcription
and TGFβ signaling but inhibits the canonical NF-κB
pathway and 50-LTR-directed transcription [4]. Unexpect-
edly, HBZ RNA was reported as sufficient to promote T
cell proliferation. The other HTLV-1 oncogene, Tax, is a
transcriptional activator of viral expression that modulates
major intracellular signaling pathways (NF-κB, CREB and
AP1) [1]. Tax immortalizes cells in vitro and induces
tumors in transgenic mouse models. Tax stimulates S
phase progression by accelerating early firing of late repli-
cation origins [6]. This process thus permits faster cell
proliferation but also engenders DNA strand breaks due
to unscheduled replication timing. This mechanism cre-
ates an oncogenic stress that triggers the DNA damage* Correspondence: luc.willems@ulg.ac.be
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reproduction in any medium, provided the orresponse (DDR) [7]. Concomitantly, Tax also attenuates
the DDR by interacting with different components of the
p53 pathway such as Chk2 [8] (Figure 1). The p53 tumor
suppressor controls cell cycle arrest allowing DNA repair
and, if damage cannot be repaired, induces apoptosis or
senescence. p53 is thus a major player that directs cell fate
upon infection by HTLV-1, as observed for a broad variety
of other viruses. The mechanisms by which Tax attenuates
p53 activity are still debated, but clearly depend on the cell
types and the experimental settings. Nonetheless, it is evi-
dent that the inactivation of p53 by gene mutation is less
frequent in ATL compared to other human neoplasms
(17-42% versus 60%) [9]. Together, these observations en-
lighten the importance of Tax-mediated inactivation of
p53 in ATL.Wild-type p53-induced phosphatase 1
In the paper by Zane et al., the predicted role of p53
was first validated in a transgenic mouse model, con-
firming previous reports. By crossing Tax-transgenic and
p53 knock-out mice, they show that tumor-free survival
is significantly shortened in a p53−/− background. The
authors next evaluated the role of Wip1 (Wild-type p53-
induced phosphatase 1), a regulator of p53. Interestingly,
Wip1 deficiency reduces Tax induced tumorigenesis in
Wip1−/− and Wip1+/− mice. Consistent with their inhibi-
tory activity, transient expression of Tax and Wip1
reduced p53 transcriptional activity in reporter assays.
Although the mechanisms still need to be further char-
acterized, a plausible model is that Tax and Wip1d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and













Figure 1 Schematic view of the Tax/p53/Wip1/MDM2/ARF
interplay. Double strands breaks (DSB) induced by Tax-driven
genomic stress are frequent in ATL cells. Recognition of these DSB by
γH2AX initiates the DNA damage response (DDR) and signals to the
p53 tumor suppressor that arrests the cell cycle, allows DNA repair, and
induces apoptosis or senescence. p53 activity is controlled by MDM2/
ARF and Wip1. MDM2 is an E3 ubiquitin ligase that degrades p53 and
is a first arm of a p53-negative feedback loop. The second mechanism
is created by Wip1 that inhibits the DDR through dephosphorylation of









Figure 2 Importance of Wip1 in modulating an oscillatory
negative feedback loop within the p53 response pathway.
Tax-induced DNA damage initiates a cascade that stimulates p53
expression. p53 then upregulates Wip1 creating a negative feedback
loop. If DNA damage has not been completely repaired during the
first pulse, the cycle repeats with a lower intensity. This mechanism
generates a series of p53 and Wip1 pulses in an oscillating pattern
that attenuates until the DNA damage is repaired.
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paper by Zane et al. thus extends previous observations
showing resistance to transformation by other onco-
genes such as Ras, Myc, E1A and Erbb2 in PPM1D defi-
cient cells [10].
Wip1 is a PP2C family serine/threonine phosphatase that
inhibits the function of several tumor suppressor pathways,
including ATM, CHK2, p38MAPK and p53 [10]. PPM1D
(protein phosphatase, Mg2+/Mn2+ dependent, 1D), the
gene encoding Wip1, is aberrantly amplified in different
types of human primary cancers. Conversely, deletion of
PPM1D in mice decreases tumorigenesis. In breast cancers,
p53 mutations are frequent, but tumors with PPM1D amp-
lification rarely harbor p53 mutations. One explanation is
that Wip1 promotes tumor formation through its ability to
inhibit p53 tumor suppressor function directly or indirectly,
thus reducing selective pressure for p53 mutations during
the progression of cancer.
The paper by Zane et al. is important because it reveals
the potential oncogenic role of Wip1 in Tax-mediated
oncogenesis in a model of ATL. A series of open questionsremain regarding the biological relevance of Wip1 in
patients and the mechanisms involved. First, it is currently
unknown if gene amplification of PPM1D occur in ATL as
observed in other types of cancers. Like p53 deletions
[9,11], PPM1D genomic amplifications usually appear at
late stages of tumorigenesis. Alternatively, it is possible
that expression and/or activity of Wip1 are increased in
the absence of genomic alteration. The PPM1D promoter
contains at least two types of transcription binding sites:
one for p53 that creates a negative feedback loop (Figure 1)
and another for c-Jun [10]. Current data show that Tax,
despite its ability to stimulate AP1, does not activate
PPM1D expression in reporter assays. Moreover, Wip1
mRNA expression is not increased in Tax-positive cells.
This observation needs to be further validated at the pro-
tein level using a larger number of HTLV-1 infected cell
lines as well as in patients’ samples. Confocal microscopy
indicates that Tax and Wip1 colocalize in the nucleus.
Further experiments will be required to determine direct
or indirect binding between Wip1 and Tax. However,
interactomic and proteomic analyzes currently suggest
that both proteins do not physically interact (JC Twizere
and OJ Semmes, personal communications).
In the context of HTLV-1 associated oncogenesis, it
will be interesting to assess the role of other viral onco-
genes like HBZ in the Tax/Wip1/p53 interplay. As an in-
hibitor of AP1 activity, HBZ might interfere with Wip1
expression. Combined crosses between Tax, Wip1, p53
and HBZ transgenic and knock-out mice could address
this question. In this context, it is noteworthy that
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accelerates osteosarcoma formation further supporting
the role of p53 regulation in Tax-induced oncogenesis
[12]. ARF is a sensor of hyperproliferative signals such
as those from the Ras and Myc oncoproteins. In re-
sponse to oncogenic stress, ARF causes cell-cycle arrest
in G1 and G2/M and is associated with increased p53
and p21 expression. ARF mediates cell-cycle arrest by
directly binding to MDM2 and sequesters it in the nu-
cleolus. Sequestration of MDM2 stabilizes and activates
p53 which then blocks cellular proliferation. Although
ARF does not appear to be aberrantly expressed in ATLL
cells [9], acceleration of Tax-induced tumor formation in
ARF-deficient mice further supports the central role
exerted by p53.
Of particular interest is the Wip1-dependent regula-
tion of ATM-CHK2 signaling on the dynamics of p53-
dependent response to DNA damage [10]. In fact,
recruitment of γH2AX to double strand breaks initiates
a cascade that produces different levels of p53 depending
on the level of damage. This mechanism also initiates a
series of p53 pulses in a repetitive pattern that shapes p53
protein level dynamics in an oscillating manner due to posi-
tive and negative feedback loops (Figure 2). If DNA damage
has not been completely repaired during the first pulse, the
cycle repeats with a lower intensity. MDM2 and Wip1 are
two essential components of this feedback loop. Upregula-
tion of p53 during the first pulse activates transcription of
MDM2 and Wip1 which, in turn, can feedback negatively
to p53 and ATM-Chk2, respectively. Disequilibrium in this
intricate network could lead to incomplete DNA repair.
What are the outcomes of these observations in terms
of therapy of ATL? First, Tax-repressed p53 function in
HTLV-1-transformed cells is druggable and can be
restored by treatment with 9-aminoacridine in a setting
absent for p53 genomic alterations [13]. Secondly, ar-
senic trioxide, which has been recently proposed to pre-
vent relapse of ATL lymphoma patients [14], augments
Chk2/p53-mediated apoptosis by inhibiting Wip1 [15].
Thirdly, Wip1 can directly be targeted by specific inhibi-
tors such as compound M (mercury, [4-Aminophenyl]
[6-thioguanosinato-N7,S6]), CCT007093 ([2E,5E]-2,5-Bis
[2-thienylmethylene]-cyclopentanone) or thioether cyclic
phosphopeptide c (MpSIpYVA) [10]. Alternatively, phos-
phorothioate antisense oligonucleotides targeting PPM1
and specifically disrupting the binding of ATM–Wip1 or
CHK2–Wip1 may be instrumental providing that deliv-
ery issues are solved.Conclusion
In summary, the paper by Zane et al. adds a new piece
in the complex puzzle of Tax-induced oncogenesis and
reveals a potential new mechanism of p53 attenuationduring HTLV-1 pathogenesis opening interesting pro-
spects for therapy.
Competing interests
The authors declare no competing financial interests.
Authors’ contributions
NG, AC, PYB and LW wrote and approved the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported by the “Fonds National de la Recherche
Scientifique” (FNRS), the Télévie, the Belgian Foundation against Cancer, the
Sixth Research Framework Programme of the European Union (project INCA
LSHC-CT-2005-018704), the “Neoangio” excellence program and the
“Partenariat Public Privé” PPP INCA of the “Direction générale des
Technologies, de la Recherche et de l’Energie/DG06” of the Walloon
government, the “Action de Recherche Concertée Glyvir” of the
“Communauté française de Belgique”, the “Centre anticancéreux près ULg”
(CAC), the “Synbiofor” project of GxABT, the “ULg Fonds Spéciaux pour la
Recherche”, the “Plan Cancer” of the “Service Public Fédéral,” and the
Interuniversity Attraction Poles (IAP) Program BELVIR initiated by the Belgian
Science Policy Office. We thank the GIGA technology platforms. NG
(postdoctoral researcher), AC (Télévie fellow), PYB (research fellow) and LW
(Research Director) are members of the FNRS. We thank KT Jeang for
comments and JC Twizere and OJ Semmes for personal communication of
unpublished work.
Received: 16 November 2012 Accepted: 15 December 2012
Published: 21 December 2012
References
1. Boxus M, Willems L: Mechanisms of HTLV-1 persistence and
transformation. Br J Cancer 2009, 101(9):1497–1501.
2. Martin F, Bangham CR, Ciminale V, Lairmore MD, Murphy EL, Switzer WM,
Mahieux R: Conference highlights of the 15th international conference
on human retrovirology: HTLV and related retroviruses, 4–8 june 2011,
leuven, gembloux, Belgium. Retrovirology 2011, 8:86.
3. Twizere JC, Kruys V, Lefebvre L, Vanderplasschen A, Collete D, Debacq C, Lai
WS, Jauniaux JC, Bernstein LR, Semmes OJ, et al: Interaction of retroviral
Tax oncoproteins with tristetraprolin and regulation of tumor necrosis
factor-alpha expression. J Nat Cancer Institute 2003, 95(24):1846–1859.
4. Zhao T, Matsuoka M: HBZ and its roles in HTLV-1 oncogenesis. Front
Microbiol 2012, 3:247.
5. Hagiya K, Yasunaga J, Satou Y, Ohshima K, Matsuoka M: ATF3, an HTLV-1
bZip factor binding protein, promotes proliferation of adult T-cell
leukemia cells. Retrovirology 2011, 8:19.
6. Boxus M, Twizere JC, Legros S, Kettmann R, Willems L: Interaction of
HTLV-1 Tax with minichromosome maintenance proteins accelerates the
replication timing program. Blood 2012, 119(1):151–160.
7. Boxus M, Willems L: How the DNA damage response determines the fate
of HTLV-1 Tax-expressing cells. Retrovirology 2012, 9:2.
8. Durkin SS, Guo X, Fryrear KA, Mihaylova VT, Gupta SK, Belgnaoui SM, Haoudi
A, Kupfer GM, Semmes OJ: HTLV-1 Tax oncoprotein subverts the cellular
DNA damage response via binding to DNA-dependent protein kinase.
J Biol Chem 2008, 283(52):36311–36320.
9. Takemoto S, Trovato R, Cereseto A, Nicot C, Kislyakova T, Casareto L,
Waldmann T, Torelli G, Franchini G: p53 stabilization and functional
impairment in the absence of genetic mutation or the alteration of the
p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/
lymphoma cells. Blood 2000, 95(12):3939–3944.
10. Le Guezennec X, Bulavin DV: WIP1 phosphatase at the crossroads of
cancer and aging. Trends biochem sci 2010, 35(2):109–114.
11. Dequiedt F, Kettmann R, Burny A, Willems L: Mutations in the p53
tumor-suppressor gene are frequently associated with bovine leukemia
virus-induced leukemogenesis in cattle but not in sheep. Virology 1995,
209(2):676–683.
12. Rauch DA, Hurchla MA, Harding JC, Deng H, Shea LK, Eagleton MC,
Niewiesk S, Lairmore MD, Piwnica-Worms D, Rosol TJ, et al: The ARF tumor
suppressor regulates bone remodeling and osteosarcoma development
in mice. PLoS One 2010, 5(12):e15755.
Gillet et al. Retrovirology 2012, 9:115 Page 4 of 4
http://www.retrovirology.com/content/9/1/11513. Jung KJ, Dasgupta A, Huang K, Jeong SJ, Pise-Masison C, Gurova KV, Brady
JN: Small-molecule inhibitor which reactivates p53 in human T-cell
leukemia virus type 1-transformed cells. J Virol 2008, 82(17):8537–8547.
14. Bazarbachi A, Suarez F, Fields P, Hermine O: How I treat adult T-cell
leukemia/lymphoma. Blood 2011, 118(7):1736–1745.
15. Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, Tsukuda Y, Tsukada
J, Kondo T, Tanaka Y, Minami Y: Arsenic trioxide augments
Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1
phosphatase. J Biol Chem 2008, 283(27):18969–18979.
doi:10.1186/1742-4690-9-115
Cite this article as: Gillet et al.: WIP1 deficiency inhibits HTLV-1 Tax
oncogenesis: novel therapeutic prospects for treatment of ATL?.
Retrovirology 2012 9:115.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
